NEW YORK ( TheStreet) -- Genzyme Corporation (Nasdaq: GENZ) hit a new 52-week high Wednesday as it traded at $76.10 compared with its previous 52-Week high of $76.09. Genzyme is changing hands at $76.08 with 210,583 shares traded as of 9:41 a.m. ET. Average volume has been five million shares over the past 30 days. Genzyme has a market cap of $19.8 billion and is part of the health care sector and drugs industry. Shares are up 6.8% year to date as of the close of trading on Tuesday. Genzyme Corporation operates as a biotechnology company worldwide. It focuses on rare genetic disease disorders, renal diseases, orthopaedics, cancers, transplant and immune diseases, and diagnostic and predictive testing areas. The company has a P/E ratio of 632.8, above the average drugs industry P/E ratio of 48.4 and above the S&P 500 P/E ratio of 16.1.
- Practice your GENZ trading strategies and win cash in our stock game.